

Remarks

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

Claims 16-19 are pending and are indicated to be allowed.

The objection to the specification is obviated in view of the above amendments to the drawings (as shown in the Annotated Sheet attached hereto) and replacement sequence listing filed herewith. In particular, applicants have amended Figure 65 and the sequence listing for SEQ ID NO:148 to correct an obvious error. More specifically, applicants have amended the sequence shown in Figure 65 and SEQ ID NO:148 to show a missing glutamine at position 271, which was clearly encoded by the nucleic acid of SEQ ID NO:147 (shown in Figure 64). Since this amendment corrects an obvious error based on the disclosure of SEQ ID NO:147, no new matter has been added.

In view of all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: October 6, 2009

/Georgia Evans/
Georgia Evans
Registration No. 44,597

NIXON PEABODY LLP
1100 Clinton Square
Rochester, New York 14604
Telephone: (585) 263-1000
Facsimile: (585) 263-1600